Actual Medicinal Product (AMP) Daraprim 25mg tablets (GlaxoSmithKline UK Ltd)

Stability Information

(Some stability information inherited from generic)

Stability

Lack of data and/or stability concerns exist. MCA use may be acceptable but is likely to be off-label and require mitigation measures. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.

Notes

Light sensitive medicine. Store in light resistant container. Moisture sensitive medicine. Store in airtight (sealed) MCA.  Manufacturer recommends storing in original container.
No stability data in MCAs available.

Provenance

This recommendation is based on the products Daraprim 25mg tablets (GlaxoSmithKline UK Ltd).

Generic

Pyrimethamine

Formulation

Pyrimethamine 25mg tablets